Financial reports
10-Q
2023 Q3
Quarterly report
9 Nov 23
ARS
2022 FY
Annual report to shareholders
25 Aug 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
31 Mar 22
Current reports
8-K
Entry into a Material Definitive Agreement
17 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
3 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
3 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Sep 23
8-K
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
2 Aug 23
8-K
Regulation FD Disclosure
5 Jun 23
8-K
Regulation FD Disclosure
25 May 23
8-K
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
16 May 23
8-K
Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates
10 May 23
8-K
Aravive Appoints Carolina Petrini as Chief Commercial Officer
11 Apr 23
Registration and prospectus
15-12G
Securities registration termination
8 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
Proxies
DEFR14A
Revised proxy
22 Sep 23
DEF 14A
Definitive proxy
5 Sep 23
PRE 14A
Preliminary proxy
24 Aug 23
DEFA14A
Additional proxy soliciting materials
3 Jan 23
DEF 14A
Definitive proxy
30 Nov 22
PRE 14A
Preliminary proxy
17 Nov 22
DEF 14A
Definitive proxy
4 Aug 22
DEFA14A
Additional proxy soliciting materials
21 Mar 22
DEF 14A
Definitive proxy
11 Feb 22
PRE 14A
Preliminary proxy
1 Feb 22
Other
EFFECT
Notice of effectiveness
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
EFFECT
Notice of effectiveness
28 Jun 23
CORRESP
Correspondence with SEC
26 Jun 23
UPLOAD
Letter from SEC
23 Jun 23
UPLOAD
Letter from SEC
22 May 23
CORRESP
Correspondence with SEC
10 May 23
Ownership
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Artal International S.C.A.
9 Feb 24
4
Maria Carolina Petrini
11 Apr 23
3
Maria Carolina Petrini
11 Apr 23
SC 13G
BAKER BROS. ADVISORS LP
14 Feb 23
SC 13G/A
Artal International S.C.A.
13 Feb 23
4
Gail Frances McIntyre
2 Feb 23
4
Robert B. Geller
2 Feb 23
4
RUDY HOWARD
2 Feb 23